Press Releases

  April 9, 2018
NEW STORY CEL-SCI Corporation to Present at The Microcap Conference
  April 4, 2018
NEW STORY CEL-SCI Issues Letter to Shareholders
  April 3, 2018
NEW STORY CEL-SCI Announces Adjustment to Warrant Exercise Price
  February 23, 2018
NEW STORY CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued In December 2016
  February 12, 2018
NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results
  February 12, 2018
NEW STORY CEL-SCI to Present Tomorrow at 2018 BIO CEO & Investor Conference
  February 5, 2018
NEW STORY CEL-SCI to Present at 2018 BIO CEO & Investor Conference
  January 30, 2018
NEW STORY U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology
  January 16, 2018
NEW STORY CEL-SCI Announces Adjustment to Warrant Exercise Price
  January 8, 2018
NEW STORY CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
  January 3, 2018
NEW STORY CEL-SCI Issues Letter to Shareholders
  December 29, 2017
NEW STORY CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments
  December 18, 2017
NEW STORY CEL-SCI Announces Robert Watson Joins Its Board of Directors
  December 11, 2017
NEW STORY CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
  December 7, 2017
NEW STORY CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
  November 28, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016
  November 13, 2017
NEW STORY CEL-SCI Announces Update on Arbitration against Former Clinical Research Organization
  October 10, 2017
NEW STORY CEL-SCI Granted European Patent for Multikine's Mechanism of Action in Making Tumors 'Visible' To the Immune System
  October 5, 2017
NEW STORY CEL-SCI Announces Update on Ongoing Arbitration Against Former Clinical Research Organization
  Septembe 19, 2017
NEW STORY CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine
  Septembe 11, 2017
NEW STORY CEL-SCI to Present Today At the 19th Annual Rodman & Renshaw Global Investment Conference
  August 30, 2017
NEW STORY CEL-SCI to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 11, 2017
  August 29, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued In December 2016
  August 23, 2017
NEW STORY CEL-SCI Announces $3.5 Million Registered Direct Offering
  August 14, 2017
NEW STORY U.S. FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & Neck Cancer Trial
  August 9, 2017
CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016
  August 9, 2017
CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results
  July 6, 2017
CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016
  June 12, 2017
CEL-SCI Announces Reverse Stock Split
  June 8, 2017
CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal
  June 7, 2017
CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016
  June 5, 2017
CEL-SCI Submits FDA Response for Its Phase 3 Head and Neck Cancer Trial
  May 24, 2017
CEL-SCI Corporation Releases Letter to Shareholders
  May 16, 2017
CEL-SCI Scientist Presents At AAI - IMMUNOLOGY 2017 Meeting
  May 12, 2017
CEL-SCI Announces Change to the Date of Its Annual Meeting
  May 10, 2017
CEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results
  May 1, 2017
CEL-SCI Announces $1.51 Million Registered Direct Offering
  April 28, 2017
CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office
  April 24, 2017
CEL-SCI Corporation Releases Letter to Shareholders
  April 12, 2017
CEL-SCI Scientist Presents at the World Vaccine Congress
  March 9, 2017
CEL-SCI Announces $1.5 Million Registered Direct Offering
  March 6, 2017
CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine
  February 27, 2017
CEL-SCI Announces That the NYSE MKT Approves Plan
  February 21, 2017
CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference
  February 17, 2017
CEL-SCI Announces $1.0 Million Registered Direct Offering
  February 9, 2017
CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

Press Releases - 2016

Press Releases - 2015

Press Releases - 2014

Press Releases - 2013

Press Releases - 2012

Press Releases - 2011